Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Oct 19, 2022 8:00 am EDT

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Oct 11, 2022 8:00 am EDT

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil

Aug 29, 2022 8:00 am EDT

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

Aug 15, 2022 4:01 pm EDT

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights

Aug 09, 2022 8:00 am EDT

IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022

Jul 25, 2022 8:00 am EDT

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

Jul 05, 2022 8:00 am EDT

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations

Jul 04, 2022 2:30 pm EDT

Tracking News - More Details of Marketing Progress for IceSense3™ in Mainland China

Jun 15, 2022 8:00 am EDT

IceCure's ProSense® Featured at SIR 2022 Annual Meeting in Breast Cancer Cryoablation Categorical Course

Jun 13, 2022 8:00 am EDT

IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2023 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023